Laboratory Tests. All laboratory specimens collected as a required component of a THSteps checkup (see Medicaid Provider Procedures Manual for age-specific requirements) must be submitted to the TDH Laboratory for analysis. HMO must educate providers about THSteps program requirements for submitting laboratory tests to the TDH Bureau of Laboratories.
Laboratory Tests. 13.3.1 Any specified laboratory tests of material and finished articles to be incorporated in the work shall be made by bureaus, laboratories or agencies approved by the Owner and reports of such tests shall be submitted to the Owner. The cost of the testing shall be paid for by the Contractor.
Laboratory Tests. All drug screening tests will be by generally accepted method. If the initial test report is positive, the employee will be placed on suspension without pay until the confirmation test results are known to the City. If the confirmation test report is negative, the employee will then be compensated for all time lost as if he/she had worked.
Laboratory Tests. Metering Equipment which fails any test whilst in its operational position shall be tested under laboratory conditions in accordance with the relevant Code of Practice.
Laboratory Tests. Owner will arrange and pay for materials, structural, mechanical, chemical, and other laboratory tests as required by the Construction Documents.
Laboratory Tests. Laboratory tests may include: (a) gonorrhea (geneprobe or culture); (b) serum syphilis test (c) chlamydia (geneprobe or culture)- vagina, throat or rectum; (d) miscellaneous culture - vagina, oral or rectal; (e) urinalysis; urinalysis with urine spun from sperm; (g) herpes test; (h) pregnancy test - serum or urine; and
Laboratory Tests. The Contractor shall take one litre sample from the discharge point of the dredging line and analyse and report the particle grading by weight not later than the following day. The contractor shall carry out these tests thrice at each location – one at beginning, one at end and one intermediate during dredging at each location. Should any test result indicate non-compliance with the fill specifications, they shall be reported to the Engineer's Representative immediately. The Contractor shall store the remaining portions of the samples and mark all test samples to indicate the date and location from which they were dredged. When dredging operations are in progress, if the Contractor notice any abrupt change within 1.0 m of reaching the theoretical boundary between sand and clay (as defined by the Client), the Contractor shall inform the Engineer's Representative (or suitably delegated representative) immediately, and perform the above mentioned visual and laboratory tests every 12 hrs. If the Engineer's Representative (or suitably delegated representative) considers that the visual check clearly indicates a clay material, the Contractor shall pump the dredged material in the on land clay disposal area. If the Engineer's Representative (or suitably delegated representative) considers that the visual check clearly indicates a sand material, the Contractor shall pump the dredged material to the onland sand reclamation, in conformity with the fill requirements. If the Engineer's Representative (or suitably delegated representative) considers that the visual check clearly indicates a clay material which is pumped in the on land for sand reclamation, the Engineer's Representative may then require that further sampling and testing be done, or he may instruct the immediate cessation of dredging for hydraulic fill from the area being used, and indicate a new area for dredging.
Laboratory Tests. Conduct laboratory tests to provide data on the important physical characteristics of the subsoils, essential for engineering studies and analyses. The laboratory tests will include standard classification tests, such as natural water content and grain size distribution.
Laboratory Tests. Perform laboratory testing on selected soil samples. The tests may include grain-size distribution, cation exchange and natural moisture contents. The test results from the grain size analysis will be used to estimate the infiltration rates of the site soils. Based on review of the geology map of this area, the project alignment is underlain by alluvium, and therefore it is assumed that the empirical method based on grain size analysis to estimate long term infiltration rate is applicable.
Laboratory Tests. The following laboratory tests will be evaluated during this trial: *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. · Hematology tests, including hemoglobin, hematocrit, red blood cell count (RBC), total white blood cell count (WBC), WBC differential (neutrophils, lymphocytes, monocytes, eosinophils, basophiils) and platelet count, will be evaluated at screening and at Visit 10 (end of treatment or early exit); · Fasting blood chemistries including: albumin, alkaline phosphatase, alanine transaminase (ALT), aspartate amino transferase (AST), blood urea nitrogen (BUN), serum calcium, serum chloride, serum sodium, carbon dioxide (CO2), creatinine (and estimated creatinine clearance), direct bilirubin, gamma-glutamyl transferase (GGT), glucose, lactate dehydrogenase (LDH), serum phosphorus, serum potassium, total bilirubin, total protein, and uric acid, will be evaluated at screening, Visit 4 (week 4), Visit 5 (week 8), Visit 7 (week 16), and Visit 10 (end of treatment or early exit); · Lipid panel including total cholesterol, LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), triglycerides, apolipoprotein A, apolipoprotein B-100, and Lp (a) will be evaluated at screening and Visit 10 (end of treatment or early exit). Visit 10 (end of treatment or early exit) results for apolipoprotein A, apolipoprotein B-100, and Lp (a) will be blinded to investigators and sponsor; · Blood biomarkers including HgbA1c, C-reactive protein, adiponectin, retinol binding protein-4 (RBP-4), intercellular cell adhesion molecule (I-CAM), vascular cellular adhesion molecule (V-CAM), plasminogen activator inhibitor 1 (PAI-1) and fibrinogen, will be evaluated at screening and at Visit 10 (end of treatment or early exit). Visit 10 (end of treatment or early exit) results for all biomarkers with the exception of HgbA1c will be blinded to investigators and sponsor; · Urine microalbumin, creatinine, and albumin/creatinine ratio will be evaluated at screening and at Visit 10 (end of treatment or early exit); · Thyroid Stimulating Hormone (TSH) will be evaluated at screening; · Serology testing for Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV), and Human Immunodeficiency Virus (HIV) will be evaluated at screening; · Urine drug screen for cannabinoids, cocai...
